Working… Menu

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00416767
Recruitment Status : Completed
First Posted : December 28, 2006
Last Update Posted : May 30, 2016
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 2006
Actual Study Completion Date : July 2007
Publications of Results:
Cadiot G, Bonnetain F, Landi B, et al.: Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: preliminary results of the FFCD 0302 phase II trial with GTE participation. [Abstract] J Clin Oncol 25 (Suppl 18): A-4620, 2007.